Tag: Combination inhaler

In January 2023, the FDA approved Airsupra (albuterol/budesonide), the first and only dual-action rescue inhaler to combine a short-acting beta-agonist (SABA) with an inhaled corticosteroid (ICS). This development marks a significant shift in respiratory care, offering a new approach to managing asthma attacks and underlying inflammation simultaneously.

Over 25 million people in the U.S. have asthma, and for those with severe symptoms, understanding **what's the strongest inhaler for asthma** is a critical question. The simple answer is that it's more complicated than picking a single device, as the “strongest” option depends on whether you need quick relief or long-term inflammation control.

Chronic respiratory diseases affect hundreds of millions of people worldwide, and managing symptoms often requires combination therapy. The Fortra inhaler is a dual-action medication containing budesonide and formoterol, prescribed for the long-term, twice-daily maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD).

While there is no single "strongest inhaler," the most effective treatment depends on the specific condition, such as asthma or COPD, and the patient's needs, according to respiratory experts. The potency and type of medication, as well as its intended purpose (rescue or maintenance), are all factors that determine its therapeutic effect.

In 2023, fluticasone/salmeterol, the medication commonly known as the purple inhaler, was among the most frequently prescribed drugs in the United States. This combination inhaler is an important and widely used maintenance treatment for individuals with chronic respiratory conditions like asthma and COPD.